MR-Guided Therapy Improved Pancreatic Cancer Survival
Patients with localized, inoperable cancer saw stable tumor control with daily adaptive radiation sessions.
Updated on Oct. 6, 2026 in Cancer
Researchers at Memorial Sloan Kettering Cancer Center reported that adaptive radiotherapy significantly improved survival outcomes for patients with inoperable, localized pancreatic cancer. The study followed 123 patients who received high-dose treatments over two years.
Why it matters
Pancreatic tumors often shift position relative to healthy organs, making standard radiation difficult; this adaptive approach allows clinicians to adjust delivery in real-time to maximize dose precision. This development provides a new potential treatment avenue for patients who are not candidates for surgery.
In a study of 123 patients with localized, inoperable pancreatic cancer, researchers reported a 37.4 percent survival rate at two years and a 76.8 percent local tumor control rate. Findings are based on a median follow-up of over two years.
The players
Memorial Sloan Kettering Cancer Center
A New York-based institution specializing in the research and treatment of cancer.
Elekta
A medical technology company that develops radiation therapy equipment for cancer treatment.
The details
The treatment utilizes the Elekta Unity MR-Linac, which combines magnetic resonance imaging with a linear accelerator to visualize internal anatomy during sessions. Because pancreatic tumors move as organs shift, care teams use daily online MR imaging to re-plan the radiation dose for each of the five treatment sessions. This enables the delivery of higher radiation doses to the tumor while minimizing exposure to surrounding healthy tissues.
Timeline
Patients underwent treatment sessions between May 2020 and December 2024.
Study results were presented at the ASTRO 2026 conference on October 1, 2026.
Health Landscape
This study reflects the ongoing shift toward adaptive radiotherapy, which leverages real-time imaging to address the movement of organs during treatment. It follows the established pattern of the Elekta Unity MR-Linac clinical program to improve precision oncology.
For patients with localized pancreatic cancer who are not candidates for surgery, this research highlights an evolving alternative for tumor management. These results are worth discussing with your oncology team to understand if adaptive radiation therapy aligns with your current care plan.
The takeaway
Adaptive radiotherapy allows for more precise tumor targeting by adjusting to daily anatomical changes during treatment. Patients navigating an inoperable diagnosis should consult with a radiation oncologist about the availability of high-precision imaging systems at their local center.
Further reading
For more information on current treatment trends, see our Cancer section.
Source note: This article includes information reported by Imaging Technology News.
